Cyclacel Pharmaceuticals, Inc. CYCLACEL ANNOUNCES SELECTION OF RECOMMENDED PHASE 2 DOSE FOR CYC065 AND EVIDENCE OF DURABLE TARGET ENGAGEMENT AND MCL-1 BIOMARKER SUPPRESSION - Part 2 of study will focus on cyclin E amplif

CYCLACEL ANNOUNCES SELECTION OF RECOMMENDED

PHASE 2 DOSE FOR CYC065

AND EVIDENCE OF DURABLE TARGET ENGAGEMENT

AND MCL-1 BIOMARKER SUPPRESSION

- Part 2 of study will focus on cyclin

E amplified drug resistant solid tumors -

Berkeley Heights, NJ, August 7, 2017 - Cyclacel

Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; Cyclacel or the Company), a clinical-stage biopharmaceutical company using

cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted medicines for cancer and

other proliferative diseases, announced today the selection of a recommended Phase 2 dose (RP2D) from part 1 of a dose-escalating,

Phase 1, first-in-human, clinical study of CYC065, a Cyclin Dependent Kinase (CDK) 2/9 inhibitor. RP2D was determined to be dosing

level 6 which enrolled 9 evaluable patients with advanced cancers. Prolonged reduction of the Mcl-1 biomarker was observed in 7

out of the 9 patients for at least 24 hours following a single dose of CYC065, which was generally well tolerated. Preliminary

anticancer activity was observed in three patients with Mcl-1, MYC and Mcl-1/cyclin E amplified cancers.

early clinical results and selection of RP2D support progressing clinical evaluation of CYC065 in selected,

molecularly-defined, patient populations," said Spiro Rombotis, President and Chief Executive Officer of Cyclacel.

"Durable reduction of Mcl-1 expression in the majority of patients at RP2D is an important differentiator, as other CDK

inhibitors only do so transiently. Like other CDK inhibitors, we expect CYC065 to work best in combination with existing

anticancer drugs. Indications of anticancer activity after a single dose of CYC065 alone in patients with molecular features

related to the drug's mechanism are unexpected and potentially exciting. We plan to apply part of the net proceeds from

our July financing to progress CYC065 studies, alone and in combinations, in both liquid and solid cancers with such

molecular features. There are currently no drugs available for patients with such features. Our highest priority is to

finalize designs for a Phase 1/2 study testing CYC065 in combination with venetoclax, a Bcl-2 inhibitor approved for chronic

lymphocytic leukemia, where we believe Mcl-1 suppression will be beneficial, while in parallel enrolling a new part 2 of the

Phase 1 study in patients with advanced solid tumors."

Phase 1 first-in-human trial

The objective of part 1 of the Phase

1 dose escalating, monotherapy study was to evaluate safety, pharmacokinetics (PK), pharmacodynamics (PD) and identify RP2D.

Certain key features of the trial are as follows:

200 Connell Drive, Suite 1500, Berkeley Heights, New Jersey 07922, USA Tel +1 (908) 517 7330 Fax +1 866 271 3466

1 James Lindsay Place, Dundee, DD1 5JJ, UK Tel +44 1382 206 062 Fax +44 1382 206 067

www.cyclacel.com - info@cyclacel.com

Having successfully achieved the objectives of part 1 of the

study, part 2 has been initiated aiming to enroll patients with advanced solid tumors, and in particular cyclin E amplified tumors.

Such tumors include subsets of high grade serous ovarian and uterine cancers. Part 2 will evaluate CYC065 in a more intensive schedule

for 2 days per week for 2 weeks of a three week cycle. Biospecimens will be collected for assessment of biomarkers related to CYC065's

mechanism of action.

Cyclacel's second generation CDK2/9 inhibitor, CYC065, is being

evaluated in an ongoing, first-in-human, Phase 1 trial in patients with advanced solid tumors. In part 1, CYC065 was well tolerated,

there were robust and durable effects on the Mcl-1 biomarker and the recommended Phase 2 dose has been selected. Evidence of target

engagement was observed by decreases in target cyclin-dependent kinase substrate phosphorylation accompanied by robust and prolonged

Mcl-1 suppression in peripheral blood cells in patient samples from the study, consistent with the Company's preclinical data.

CYC065 is mechanistically similar but has much higher dose potency, in vitro and in vivo, and improved metabolic

stability than seliciclib, Cyclacel's first generation CDK inhibitor. As with palbociclib, the first CDK inhibitor approved by

FDA in 2015, and ribociclib approved in 2017, CYC065 may be most useful in combination with other anticancer agents, including

Bcl-2 antagonists, such as venetoclax, or HER2 inhibitors, such as trastuzumab.

CYC065 is a highly-selective, orally-

and intravenously-available, second generation inhibitor of CDK2 and CDK9. It causes apoptotic death of cancer cells at sub-micromolar

concentrations. Antitumor efficacy has been achieved in vivo with once a day oral dosing at well tolerated doses in preclinical

models. Evidence from published nonclinical studies show that CYC065 may benefit patients with adult and pediatric hematological

malignancies, including certain Acute Myeloid Leukemias (AML), Acute Lymphocytic Leukemias (ALL), Chronic Lymphocytic Leukemias

(CLL), B-cell lymphomas, multiple myelomas, and certain solid tumors, including breast and uterine cancers and neuroblastomas.

Independent investigators published nonclinical evidence that CYC065 induced regression or tumor growth inhibition in a model of

HER2-positive breast cancer addicted to cyclin E that is resistant to trastuzumab, reduced tumor growth in models of CCNE1-amplified

uterine serous carcinoma and reduced tumor burden and prolonged survival in several neuroblastoma models in vivo.

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage

biopharmaceutical company using cell cycle, transcriptional regulation and DNA damage response biology to develop innovative, targeted

medicines for cancer and other proliferative diseases. Cyclacel's transcriptional regulation program is evaluating CYC065, a CDK

inhibitor, in patients with advanced cancers. The DNA damage response program is evaluating a sequential regimen of sapacitabine

and seliciclib, a CDK inhibitor, in patients with BRCA positive, advanced solid cancers. Cyclacel is analyzing stratified and exploratory

subgroups from a Phase 3 study of sapacitabine in elderly patients with AML. Cyclacel's strategy is to build a diversified biopharmaceutical

business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit

Forward-looking Statements

This news release contains certain forward-looking

statements that involve risks and uncertainties that could cause actual results to be materially different from historical results

or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements

regarding, among other things, the efficacy, safety and intended utilization of Cyclacel's product candidates, the conduct and

results of future clinical trials, plans regarding regulatory filings, future research and clinical trials and plans regarding

partnering activities. Factors that may cause actual results to differ materially include the risk that product candidates that

appeared promising in early research and clinical trials do not demonstrate safety and/or efficacy in larger-scale or later clinical

trials, trials may have difficulty enrolling, Cyclacel may not obtain approval to market its product candidates, the risks associated

with reliance on outside financing to meet capital requirements, and the risks associated with reliance on collaborative partners

for further clinical trials, development and commercialization of product candidates. You are urged to consider statements that

include the words "may," "will," "would," "could," "should," "believes,"

"estimates," "projects," "potential," "expects," "plans," "anticipates,"

"intends," "continues," "forecast," "designed," "goal," or the negative of those

words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties

the Company faces, please refer to our most recent Annual Report on Form 10-K and other periodic and other filings we file with

the Securities and Exchange Commission and are available at www.sec.gov. Such forward-looking statements are current only as of

the date they are made, and we assume no obligation to update any forward-looking statements, whether as a result of new information,

future events or otherwise.

Copyright 2017 Cyclacel Pharmaceuticals,